Immatics N.V. (IMTX)
NasdaqCM · USD · Healthcare · Biotechnology
$7.33 (+2.45%) as of
Key statistics
- Market cap
- 1.12B
- Forward P/E
- -3.63
- EPS (TTM)
- -1.83
- Dividend yield
- 0.00%
- 52-week range
- 6.65 – 12.41
- Beta
- 1.36
- Revenue (TTM)
- 41.7M
- Profit margin
- 0.00%
- Analyst target
- $16.97
- Volume
- 61.43k
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Tübingen, Germany
- Employees
- 704
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.